Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).
1 finding from 1 review
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
1 finding from 1 review
Adverse events Beta‐estradiol patch 0.05 or 0.1 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Frequency of hot flushes Oral beta‐estradiol 1.0 and 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Adverse events Oral beta‐estradiol 1.0 or 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day · women with hot flushes
Transdermal beta‐estradiol patch showed no clear difference in intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day compared with placebo (low certainty).
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
1 finding from 1 review
Adverse effects Beta‐estradiol gel dose 1.5 mg/day · women with hot flushes
1 finding from 1 review
Pain‐free at 2 hours · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Pain‐free at different time points (1, 4, 24 hours) · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Use of rescue medication · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Any adverse event · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Specific adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low